Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Proton magnetic resonance spectroscopy (1 H-MRS) is sensitive to early neurodegenerative processes associated with Alzheimer's disease (AD). Although 1 H-MRS metabolite ratios of N-acetyl aspartate (NAA)/creatine (Cr), NAA/myoinositol (mI), and mI/Cr measured in the posterior cingulate gyrus reveal evidence of disease progression in AD, pathologic underpinnings of the 1 H-MRS metabolite changes in AD are unknown. Pathologically diagnosed human cases ranging from no likelihood to high likelihood AD (n= 41, 16 females and 25 males) who underwent antemortem 1 H-MRS of the posterior cingulate gyrus at 3 tesla were included in this study. Immunohistochemical evaluation was performed on the posterior cingulate gyrus using antibodies to synaptic vesicles, hyperphosphorylated tau (pTau), neurofibrillary tangle conformational-epitope (cNFT), amyloid-β, astrocytes, and microglia. The slides were digitally analyzed using Aperio software, which allows neuropathologic quantification in the posterior cingulate gray matter. MRS and pathology associations were adjusted for time from scan to death. Significant associations across AD and control subjects were found between reduced synaptic immunoreactivity and both NAA/Cr and NAA/mI in the posterior cingulate gyrus. Higher pTau burden was associated with lower NAA/Cr and NAA/mI. Higher amyloid-β burden was associated with elevated mI/Cr and lower NAA/mI ratios, but not with NAA/Cr.1 H-MRS metabolite levels reveal early neurodegenerative changes associated with AD pathology. Our findings support the hypothesis that a decrease in NAA/Cr is associated with loss of synapses and early pTau pathology, but not with amyloid-β or later accumulation of cNFT pathology in the posterior cingulate gyrus. In addition, elevation of mI/Cr is associated with the occurrence of amyloid-β plaques in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“The utilization of neuroimaging as an Alzheimer’s disease (AD) biomarker has been included in the most recent NIA-AA consensus recommendations on diagnostic guidelines (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationNo adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · cited 1×
“Standardized methods for sampling and neuropathologic examination were performed according to the The Consortium to Establish a Registry for Alzheimer’s Disease and the Third Report of the Dementia with Lewy bodies Consortium (Mirra et al., 1991; McKeith et al., 2005).”
MethodSelf-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 2×
“The utilization of neuroimaging as an Alzheimer’s disease (AD) biomarker has been included in the most recent NIA-AA consensus recommendations on diagnostic guidelines (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“SV2A is a synaptic vesicle protein that has been implicated as a target site for the anti-epileptic drug levetiracetam (Lynch et al., 2004), and recently evaluated as a potential therapeutic target in mild cognitive impairment (MCI) (Bakker et al.”
BackgroundHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Cited by
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12321 · Cited by 330
Self-citationConserved brain myelination networks are altered in Alzheimer’s and other neurodegenerative diseases
Allen, M., Wang, X., Burgess, J. D., Watzlawik, J., Serie, D. J., Younkin, C. S., Nguyen, T., Malphrus, K. G., Lincoln, S., Carrasquillo, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.012 · Cited by 143
“Myelination patterns were assessed in a subset of AD, PSP, and control TCX samples (four each) using established immunohistochemistry methods [26,27].”
Self-citationKodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Daulatzai, M. A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1404-6 · Cited by 63
Metadata
- Authors
- Murray, M. E., Przybelski, S. A., Lesnick, T. G., Liesinger, A. M., Spychalla, A., Zhang, B., Gunter, J. L., Parisi, J. E., Boeve, B. F., Knopman, D. S., Petersen, R. C., Jack, C. R., Dickson, D. W., & Kantarci, K.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2014-12-03
- Volume
- 34
- Issue
- 49
- Pages
- 16247-16255
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2054163710
- Cited by
- 148
- References
- 19
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. https://app.cochat.ai/papers/10.1523/jneurosci.2027-14.2014
- The paper
- Murray, M. E., Przybelski, S. A., Lesnick, T. G., Liesinger, A. M., Spychalla, A., Zhang, B., Gunter, J. L., Parisi, J. E., Boeve, B. F., Knopman, D. S., Petersen, R. C., Jack, C. R., Dickson, D. W., & Kantarci, K. (2014). Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.2027-14.2014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.